The first licensed drug proven to be effective in preventing migraines may soon be available in the UK, after EU regulators gave it the green light.
The European Medicines Agency has approved Erenumab, specifically designed to prevent the onset of migraines, opening the door for the treatment to be made available on the NHS.
“Even were it turned down by public health officials, the manufacturer Novartis has said that patients would be able to access the medicine privately from September,” Sky News reports. The drug, which can be injected by the patient at home, works by blocking a receptor in the brain which is believed to be involved in triggering migraines - “although scientists are not completely sure what causes the agonising headaches just yet”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In clinical trials, “one in four patients with chronic migraines - those experiencing symptoms 15 days or more a month - were migraine-free for more than 15 months,” The Scientist reports.
On average, Erenumab cut the number of days that volunteers experienced a migraine in a month by half.
Wendy Thomas, the chief executive of the Migraine Trust, said the decision to approve the drug for sale in the EU was “wonderful”.
“This new treatment has the potential to help many people with chronic and episodic migraine,” she said, a condition which “can literally ruin lives”.
A world survey of health conditions across 195 countries found that, “in every year from 1990 to 2016, migraine attacks remained the second-largest global contributor to years lived with disability”, writes journalist and migraine sufferer Lauren Sharkey for the BBC.
As well as causing misery for millions, migraines also come with an economic cost. In the UK alone, the extreme headaches are responsible for around 25 million sick days taken every year.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
Why is the government on the brink of a shutdown?Today's Big Question GOP infighting is bringing the country to a standstill, but even Republicans aren't entirely sure why
-
Today’s political cartoons — September 29, 2023
Friday's cartoons - Biden's dog bite incident, the government shutdown and more
-
'A teetering democracy of gerontocrats?'
Instant opinion Opinion, comment and editorials of the day
-
Fixing the NHS workforce
The Explainer There are roughly 112,000 vacant posts in NHS England with nearly one in ten posts unfilled
-
Surgery faces ‘MeToo moment’ as female staff assaulted while operating
Two-thirds of women surgeons claim to have been sexually harassed and a third alleged assaults
-
What does UK’s first womb transplant mean for future of fertility?
Today's Big Question Procedure could be offered more widely including to transgender people
-
The NHS plan for virtual wards to beat winter crisis
feature Patients with respiratory infections to be given wearable devices that allow doctors to monitor them at home
-
The NHS at 75: can it make it to 100?
feature The NHS is facing almost unprecedented challenges, but support for the institution remains strong with the public
-
Rishi Sunak’s NHS plan explained in five points
feature More apprenticeships and increased technology among ‘historic’ proposals
-
ADHD: the trouble with diagnosis
feature Waiting times for an NHS assessment for ADHD are years long in some parts of the UK
-
The racial disparities in British maternity deaths
feature Black women are nearly four times more likely to die in pregnancy and childbirth than white women
